Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftobiprole vs Linezolid/Ceftazidime in Nosocomial Pneumonia
NCT00229008Phase 3Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Nov 2005
- Primary completion
- May 2007
- Modality
- Reversible Covalent Inhibitors
01
Overview
Phase 3, randomised, double-blind trial of ceftobiprole medocaril in hospital-acquired pneumonia (HAP) (2 arms), sponsored by Basilea Pharmaceutica. Primary endpoint: Clinical cure rate. Started Nov 2005; status: completed.
02
Drugs
ceftobiprole medocaril
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on NCT00229008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00229008.